Picture of AbCellera Biologics logo

ABCL — AbCellera Biologics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

AbCellera Q2 net loss widens on higher expenses

AbCellera Q2 net loss widens on higher expenses


Overview

  • US biotechnology firm's Q2 revenue declined and missed analyst expectations

  • Net loss widened to $55.4 mln from $34.7 mln a year earlier

  • Company signed new collaborations with Jazz and Vertex, adding over $100 mln upfront cash


Outlook

  • Company expects top-line data from ABCL635 Phase 2 trial in August 2026

  • Top-line data from ABCL575 Phase 1 study expected in Q4 2026

  • AbCellera to receive over $100 mln in upfront cash from recent collaborations


Result Drivers

  • R&D SPENDING - Co said higher research and development expenses contributed to wider net loss

  • NEW COLLABORATIONS - Co signed deals with Jazz and Vertex, adding over $100 mln in upfront cash


Company press release: ID:nBw2ZPClLa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Miss

$4.1 mln

$7.78 mln (7 Analysts)

Q2 Net Loss

$55.4 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for AbCellera Biologics Inc. is $11.00, about 80.6% above its August 4 closing price of $6.09


Reuters Recommended Reads

  • Aug 3 - Ireland's Jazz Pharma Q2 revenue beats estimates on Zepzelca higher sales

  • Aug 3 - Vertex Q2 revenue beats estimates on strong demand for cystic fibrosis therapies, lifts outlook

  • Aug 5 - Recursion Pharmaceuticals Q2 revenue misses estimates, cuts 2026 expense outlook


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on AbCellera Biologics

See all news